Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROBE: AMDX-2011P in Parkinson's and ALS
NCT05542576Phase 2Completed
- Sponsor
- Amydis
- Start
- Aug 2022
- Primary completion
- Mar 2023
- Modality
- Device-based Delivery, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of AMDX-2011P in Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), sponsored by Amydis. Started Aug 2022; status: completed.
02
Drugs
AMDX-2011P
03
Conditions
Parkinson's disease (PD)amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05542576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05542576.